About hemophilia A
Hemophilia is a rare bleeding disorder caused by deficiency of clotting factors such as VIII and IX. It is an X-linked recessive disorder, which is more prevalent in males than in females. It is estimated that it affects around 400,000 people per year. The two major types of hemophilia are A and B. Hemophilia A, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII. It is transmitted genetically from parent to child during birth. Recombinant clotting factors or plasma-derived clotting factors are being developed for the treatment of this disorder.
Technavio's analysts forecast the global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy.
Technavio's report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• Europe
Key vendors
• Baxter International
• Bayer's
• CSL Behring
• Novo Nordisk
• Pfizer
Other prominent vendors
• Alnylam Pharmaceuticals
• Amarna Therapeutics
• Asklepios
• Biogen Idec
• Catalyst Biosciences
• Dimension Therapeutics
• Dong-A Socio
• Emergent BioSolutions
• Grifols
• Inspiration Biopharmaceuticals
• Kedrion Biopharma
• Octapharma
• OPKO Health
• rEVO Biologics
• Sangamo BioSciences
• Spark Therapeutics
• UniQure
Market driver
• Development of drugs with prolonged action
• For a full, detailed list, view our report
Market challenge
• High cost of therapy
• For a full, detailed list, view our report
Market trend
• Advances in technology
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Risk Factors
Signs and symptoms
Diagnosis
Treatment
Epidemiology
PART 06: Pipeline portfolio
Key Information on pipeline candidates
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Segmentation by type of therapy
Plasma derived therapies
Recombinant therapies
PART 09: Segmentation by disease management
On-demand therapy
Prophylaxis
Inhibitors
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 17: Key vendor analysis
Baxter
Bayer HealthCare
CSL Behring
Novo Nordisk
Pfizer
PART 18: Appendix
List of abbreviation